© Copyright 2025 American Medical Association. All rights reserved.
This CPT® code 90644 refers to a specific combination vaccine designed to protect against meningococcal disease caused by the serogroups C and Y, as well as Haemophilus influenzae type b (Hib). Meningococcal disease is a serious infection caused by the bacterium Neisseria meningitides, which can lead to severe health complications such as septicemia and meningitis. The vaccine is particularly important as it targets two specific serogroups, C and Y, out of the 13 known subtypes of Neisseria meningitides, thereby providing essential immunity against these strains. Additionally, Hib infections can result in various serious conditions, including pneumonia, epiglottitis, and infections of the joints and bones, as well as meningitis. The formulation of this vaccine is specifically intended for children aged 6 weeks to 18 months, ensuring that this vulnerable population receives the necessary protection during a critical period of their immune development. It is important to note that this code pertains solely to the supply of the combination vaccine itself; an additional administration code must be reported for the actual intramuscular injection of the vaccine.
© Copyright 2025 Coding Ahead. All rights reserved.
This vaccine is indicated for the prevention of meningococcal disease caused by serogroups C and Y, as well as for the prevention of infections caused by Haemophilus influenzae type b (Hib). The target population for this vaccine includes children aged 6 weeks to 18 months, who are at a higher risk for these infections due to their developing immune systems.
The administration of the Hib-MenCY vaccine involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine.
Post-procedure care involves monitoring the child for any immediate adverse reactions, which may include mild fever, redness, or swelling at the injection site. Caregivers should be informed about common side effects and advised to seek medical attention if severe reactions occur. Additionally, it is important to schedule follow-up appointments for subsequent doses of the vaccine as part of the 4-dose schedule to ensure full immunization against meningococcal disease and Hib infections.
Short Descr | HIB-MENCY VACC 6WK-18M0 IM | Medium Descr | HIB-MENCY VACC 4 DOSE SCHED 6 WKS-18 MONTHS IM | Long Descr | Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 9 - Other Medical Items or Services | Berenson-Eggers TOS (BETOS) | P6C - Minor procedures - other (Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit |
Date
|
Action
|
Notes
|
---|---|---|
2017-01-01 | Changed | Long, Medium and Short descriptions changed. |
2016-01-01 | Changed | First appearance of 2015 change in codebook. |
2016-01-01 | Changed | Description Changed |
2015-07-01 | Changed | Description Changed |
2012-01-01 | Changed | Description Changed |
2011-01-01 | Added | First appearance in code book |
2010-01-01 | Added | Implemented |
Get instant expert-level medical coding assistance.